Varicella-zoster virus infections in immunocompromised patients - a single centre 6-years analysis
Authors:
- Verena WiegeringVWVerena Wiegering
- Judith SchickJSJudith Schick
- Meinrad BeerMBMeinrad Beer
- Benedikt WeissbrichBWBenedikt Weissbrich
- Stefan GattenlöhnerSGStefan Gattenlöhner
- Hermann J GirschickHGHermann J Girschick
- Johannes LieseJLJohannes Liese
- Paul G SchlegelPSPaul G Schlegel
- Matthias EyrichMEMatthias Eyrich
Open Access
- 10 May 2011
- journal article
- case report
- Published by Springer Nature in BMC Pediatrics
- Vol. 11 (1) , 31
Abstract
Background: Infection with varicella-zoster virus (VZV) contemporaneously with malignant disease or immunosuppression represents a particular challenge and requires individualized decisions and treatment. Although the increasing use of varicella-vaccines in the general population and rapid initiation of VZV-immunoglobulins and acyclovir in case of exposure has been beneficial for some patients, immunocompromised individuals are still at risk for unfavourable courses.Methods: In this single center, 6-year analysis we review incidence, hospitalization and complication rates of VZV-infections in our center and compare them to published data. Furthermore, we report three instructive cases.Results: Hospitalization rate of referred children with VZV-infections was 45%, among these 17% with malignancies and 9% under immunosuppressive therapy. Rate of complications was not elevated in these two high-risk cohorts, but one ALL-patient died due to VZV-related complications. We report one 4-year old boy with initial diagnosis of acute lymphoblastic leukemia who showed a rapidly fatal outcome of his simultaneous varicella-infection, one 1.8-year old boy with an identical situation but a mild course of his disease, and an 8.5-year old boy with a steroid-dependent nephrotic syndrome. This boy developed severe hepatic involvement during his varicella-infection but responded to immediate withdrawl of steroids and administration of acyclovir plus single-dose cidofovir after nonresponse to acyclovir after 48 h.Conclusion: Our data show that patients with malignant diseases or immunosuppressive therapy should be hospitalized and treated immediately with antiviral agents. Despite these measures the course of VZV-infections can be highly variable in these patients. We discuss aids to individual decision-making for these difficult situations.Keywords
This publication has 18 references indexed in Scilit:
- Neurologic Varicella Complications Before Routine Immunization in GermanyPediatric Neurology, 2010
- The Burden of Varicella Complications Before the Introduction of Routine Varicella Vaccination in GermanyThe Pediatric Infectious Disease Journal, 2008
- FATAL VISCERAL VARICELLA-ZOSTER VIRUS INFECTION WITHOUT SKIN INVOLVEMENT IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIAPediatric Hematology and Oncology, 2008
- Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatmentSupportive Care in Cancer, 2005
- Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus InfectionsClinical Microbiology Reviews, 2003
- Infecciones por virus varicela zoster en menores de 15 años con cáncerRevista médica de Chile, 2003
- Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 2003
- Noncutaneous varicella‐zoster virus (VZV) infection with fatal liver failure in a child with acute lymphoblastic leukemia (ALL)Medical and Pediatric Oncology, 2001
- Novel agents for the therapy of varicella-zoster virus infectionsExpert Opinion on Investigational Drugs, 2000
- Acute myeloblastic leukemia with hyperleukocytosis: Risk factors for early mortality in inductionAmerican Journal of Hematology, 1988